Ambu acquires Invendo Medical for $265M — 4 insights

Ambu acquired Invendo Medical along with its single-use endoscope business for €225 million ($265 million.)

Here's what you should know:

1. Ambu agreed to make contingent payments up to €110 million ($129 million) as part of the deal. The contingencies were not disclosed.

2. Invendo Medical develops sterile, single-use, high-definition endoscopy products for gastroenterologists. Invendo developed the world's first single-use GI platform.

3. In 2018, Invendo expects its HD colonoscope to earn both FDA approval and a CE mark.

4. Invendo has been active in the single-use pulmonary endoscopy field to the tune of 5 million annual procedures.

Ambu CEO Lars Marcher said in a release, "This acquisition is a massive upgrade of our business potential. We introduced single-use endoscopy for airway procedures with the Ambu aScope, and now, we will get ready to introduce single-use for the gastrointestinal procedures. This is an important acquisition that puts Ambu in an ideal position to further disrupt the reusable market within endoscopy."

More articles on gastroenterology:
GI leader to know: Dr. Umaprasanna Karnam of Gut Whisperer Center for Digestive Health
Stock market week-in-review for 5 large GI companies — Oct. 16-20
To prevent injury, gastroenterologists should complete more ergonomics training, take breaks

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Top 40 Articles from the Past 6 Months